Heru Wijono

Dr. Heru Wijono

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Rika YuliaRika Yulia
Rika Yulia
PIPutri Ikasanti
Putri Ikasanti
FHFauna Herawati
Fauna Herawati
RHRuddy Hartono
Ruddy Hartono
PHPuri Safitri Hanum
Puri Safitri Hanum
HWHeru Wijono
Heru Wijono
The clinical manifestations associated with COVID-19 disease is mainly due to a dysregulated host response related to the overexpression of inflammatory markers. Until recently, only remdesivir had gained FDA approval for COVID-19 hospitalized patients and there are currently no evidence-based therapeutic options or options for prevention of complications that have been established. Some medical treatments such as antivirals, antibacterials, antithrombotics, antipyretics, corticosteroids, interleukin inhibitors, monoclonal antibodies, convalescent plasma, immunostimulants, and vitamin supplements have been utilized. However, there are limited data to support their effectiveness. Hence, this study was attempted to identify and evaluate the effectiveness of antibacterials and antivirals used for COVID-19 using a retrospective cross-sectional approach based on the medical records of adult patients in four hospitals. The number of antibacterials was calculated in defined daily dose (DDD) per 100 bed-days unit. Both mixed-logit regression and analysis of covariance were used to determine the effectiveness of the aforementioned agents in relation to COVID-19 outcome and patients’ length of stay. The model was weighed accordingly and covariates (e.g., age) were considered in the model. Heart disease was found to be the most common pre-existing condition of COVID-19 hospitalized patients in this study. Azithromycin, an antibacterial in the Watch category list, was used extensively (33–65 DDD per 100 bed-days). Oseltamivir, an antiviral approved by the FDA for influenza was the most prescribed antiviral. In addition, favipiravir was found to be a significant factor in improving patients’ COVID-19 outcomes and decreasing their length of stay. This study strongly suggests that COVID-19 patients’ received polypharmacy for their treatment. However, most of the drugs used did not reach statistical significance in improving the patients’ condition or decreasing the length of stay. Further studies to support drug use are needed.

10 June 2026 in COVID
Verified
Journal Article
Open access
PDF file
HWHeru Wijono
Heru Wijono
FHFauna Herawati
Fauna Herawati
AJAbdul Kadir Jaelani
Abdul Kadir Jaelani
SOStefani Kartika Octavia
Stefani Kartika Octavia
DRDewi Ramdani
Dewi Ramdani
Rika YuliaRika Yulia
Rika Yulia
This study analyses the pharmacological profiles of medications administered to critically ill COVID-19 patients to evaluate their efficacy regarding recovery rates and duration of hospitalization. The results demonstrate a significant difference in clinical outcomes. While the administration of Ceftazidime, Ceftriaxone, and Oseltamivir was associated with negative survival trends, Dexamethasone and Favipiravir were associated with a fourfold higher probability of survival in severe cases. Notably, no pharmacological intervention significantly reduced the length of hospital stay; instead, recovery duration was primarily influenced by comorbidities such as obesity, cardiovascular disease, and diabetes. Furthermore, age and preexisting physiological conditions remained primary predictors of mortality. Observational analysis in our study for drug repurposing identified Amikacin, Remdesivir, and Rivaroxaban as potential therapeutic candidates. However, Dexamethasone was identified as the most effective treatment for recovery, likely due to a molecular structure with high potential binding affinity to the SARS-CoV-2 virus. These findings suggest that while specific repurposed drugs offer measurable benefits, patient history remains a critical determinant of outcomes, highlighting the necessity for further research to refine therapies against emerging viral pathogens.

14 April 2025 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
PDF file
Rika YuliaRika Yulia
Rika Yulia
SHSteven Victoria Halim
Steven Victoria Halim
FHFauna Herawati
Fauna Herawati
DRDian Natasya Raharjo
Dian Natasya Raharjo
ESEko Setiawan
Eko Setiawan
HWHeru Wijono
Heru Wijono
Background and aims. Surgical site infection (SSI) remains a significant global health concern, including in Indonesia. The administration of prophylactic antibiotics plays a pivotal role in the prevention and the reduction in mortality rates associated with SSIs. Prophylactic antibiotic use is recommended in surgical procedures that are at risk of infection, including in clean surgical operations that last more than three hours and clean-contaminated surgeries. The objective of this study was to analyze the quantity of prophylactic antibiotic consumption and to compare the consumption of antibiotics between neurosurgery (clean surgery) and appendectomy (clean-contaminated surgery). Methods. Data in this observational study were obtained from the medical records of patients who underwent neurosurgery and appendectomy at two hospitals in Surabaya: one private and one public hospital. The quantity of antibiotic consumption will be analyzed descriptively and presented as a defined daily dose (DDD) per 100 bed days. Results. Research findings revealed a higher quantity of antibiotic consumption in elective neurosurgery, representing 47.43 DDD/100 bed-days, in comparison to 21.26 DDD/100 bed-days and 76.34 DDD/100 bed-days in elective and emergency appendectomy, respectively. The most frequently used antibiotics were broad-spectrum antibiotics, which included cefixime (36.91 DDD/100 bed-days) and ceftriaxone (5.45 DDD/100 bed-days) in elective neurosurgery; and ceftriaxone (14.94 vs 50.86 DDD/100 bed-days) and metronidazole (5.75 vs 19.16 DDD/100 bed-days) in elective and emergency appendectomy, respectively. Conclusion. The consumption of prophylaxis antibiotics remains a significant concern. In order to develop strategies to prevent bacterial resistance through an antibiotic stewardship program, it is essential to evaluate antibiotic consumption and monitor trends over time.